Leadership, Planning and Evaluation

领导、规划和评价：摘要 斯蒂芬森癌症中心（SCC）在监督下进行正式的规划和评估活动 SCC主任和高级领导团队，以推进其消除俄克拉荷马州癌症的使命 (SCC集水区）及以外地区。计划和评估对于矩阵癌症中心至关重要 像SCC一样，确保SCC活动和资源的最佳协调、集成和有效性 配置中以下核心战略优先事项为所有SCC研究的目标、策略和指标提供了信息 组成部分：1）提高癌症研究的广度，深度和影响力; 2）促进翻译 3）设计和进行假设驱动的试验， 改善癌症患者或癌症高危人群的治疗效果; 4）促进项目内和项目间的合作 和跨学科团队科学; 5）加强COE以解决优先癌症和癌症问题 6）增加学生的培训和导师机会， 教师;以及7）提高少数民族和妇女在SCC中的代表性不足 领导和成员，并在管道计划。用于监督、规划和评估研究 活动，SCC主任罗伯特Mannel，医学博士已经组建了一个经验丰富的高级领导团队， 副主任（AD）谁监督以下职能：基础研究（丹尼Dhanasekaran，博士）; 转化研究（Priyabrata Mukherjee，博士）;临床研究（Kathleen摩尔，医学博士）;社区 外展和参与（Mark Doescher，MD）;教育，培训和职业提升（Rajagopal 拉梅什博士）;多样性，公平和包容（琼步行者，医学博士）;和研究管理（韦德 威廉姆斯博士）。 自2006年Mannel被任命为SCC主任以来，战略规划和评估一直是 在SCC的发展中发挥作用。常设研究领导委员会（RLC）和研究 指导委员会（RSC）由SCC所有研究部门的领导人组成， 定期举办规划和评估进展的论坛。此外，研究领导力在以下方面也有很好的代表性： SCC临床计划和评估。科学和社区咨询委员会的外部投入增加了 这些规划和评估活动。在规划讨论中提出的新战略倡议 报告所述期间包括：研究计划调整（2018年）;与俄克拉荷马州的战略伙伴关系 老年科学中心（2018年）和哈罗德哈姆糖尿病中心（2019年）;加强SCC的新举措 研究重点是集水区优先癌症和流行癌症问题（2019年）;增加 与诺曼合作，促进以癌症为重点的研究和合作（2020年）;建立一个新的 AD在多样性、公平性和包容性方面的立场，以及如何在SCC中加强DEI的广泛规划 领导和成员，并在管道教育计划（2021年）。

LEADERSHIP, PLANNING AND EVALUATION: ABSTRACT The Stephenson Cancer Center (SCC) conducts formal planning and evaluation activities, under the oversight of the SCC director and senior leadership team, to advance its mission of eliminating cancer in Oklahoma (SCC catchment area) and beyond. Planning and evaluation are critically important for a matrix cancer center like the SCC to ensure optimal coordination, integration, and effectiveness of SCC activities and resource allocation. The following core strategic priorities inform the goals, tactics, and metrics for all SCC research components: 1) enhancing breadth, depth, and impact of cancer-focused research; 2) fostering the translation of discoveries into the clinical or community setting; 3) designing and conducting hypothesis-driven trials to improve outcomes for people with or at risk for cancer; 4) promoting intra- and inter-programmatic collaboration and transdisciplinary team science; 5) enhancing COE to address priority cancers and cancer problems prevalent in the SCC catchment area; 6) increasing training and mentorship opportunities for students and faculty; and 7) enhancing the presence of underrepresented minority persons and women among SCC leadership and membership, and in pipeline programs. For oversight, planning, and evaluation of research activities, SCC Director Robert Mannel, MD has assembled an experienced senior leadership team of associate directors (ADs) who oversee the following functions: basic research (Danny Dhanasekaran, PhD); translational research (Priyabrata Mukherjee, PhD); clinical research (Kathleen Moore, MD); community outreach and engagement (Mark Doescher, MD); education, training, and career enhancement (Rajagopal Ramesh, PhD); diversity, equity, and inclusion (Joan Walker, MD); and research administration (Wade Williams, PhD). Since Mannel’s appointment as SCC director in 2006, strategic planning and evaluation has played a central role in the development of the SCC. The standing Research Leadership Committee (RLC) and Research Steering Committee (RSC), which are comprised of leaders for all research components at the SCC, provide regular forums for planning and evaluating progress. In addition, research leadership is well represented in SCC clinical planning and evaluation. External input from scientific and community advisory boards augment these planning and evaluation activities. New strategic initiatives emerging from planning discussions during the reporting period include: research program realignment (2018); strategic partnerships with the Oklahoma Center for Geroscience (2018) and Harold Hamm Diabetes Center (2019); new initiatives to enhance SCC research focused on catchment area priority cancers and prevalent cancer problems (2019); increased engagement with OU Norman to foster cancer-focused research and collaborations (2020); establishing a new AD position for diversity, equity, and inclusion, and broad planning for how to enhance DEI among SCC leadership and membership, and in pipeline education programs (2021).